AWA
CPRX

Adapt Wealth Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Adapt Wealth Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$229K Sell
7,300
-1,700
-19% -$50.2K 0.08% 88
2026
Q1 		$223K Sell
9,000
-100
-1% -$2.38K 0.08% 93
2025
Q4 		$212K Buy
+9,100
New +$203K 0.07% 97

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adapt Wealth Advisors's CPRX Position: Q2 2026 in Review

Adapt Wealth Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 19% in Q2 2026, selling an estimated $50.2K and leaving 7,300 shares worth $229K. The position accounts for 0.08% of the portfolio, ranked #88.

Adapt Wealth Advisors first reported a position in CPRX in Q4 2025 and has held it in 3 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Adapt Wealth Advisors held 7,300 shares of Catalyst Pharmaceutical worth $229K as of Q2 2026.
  • Adapt Wealth Advisors sold 1,700 Catalyst Pharmaceutical shares in Q2 2026, an estimated $50.2K.
  • Catalyst Pharmaceutical made up 0.08% of Adapt Wealth Advisors's portfolio in Q2 2026, its #88 holding.
  • Adapt Wealth Advisors first reported a position in Catalyst Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Adapt Wealth Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.